Monday, June 27, 2022

Cannabis Science Inc (OTCMKTS:CBIS) Joins the Race

Cannabis Science Inc (OTCMKTS:CBIS) is finally starting to play along with the broad action in the cannabis-related space, helped along by an announcement touting its new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. This is a particularly well-timed announcement, and the stock is reacting with forceful upward momentum so far.

Recent action has seen 17% tacked on to share pricing for the name in the past week. The situation may be worth watching. CBIS has evidenced sudden upward volatility on many prior occasions. Moreover, the stock has seen interest climb, with an increase in recent trading volume of 82% above its longer run average levels. But this one demands a deeper look under the hood for reasons that will become clear.

Cannabis Science Inc (OTCMKTS:CBIS) frames itself as a company that develops, produces, and commercializes phyto cannabinoid-based pharmaceutical products primarily in the United States. The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.

In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.

The company also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug. Cannabis Science, Inc. is based in Colorado Springs, Colorado. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.

Find out when $CBIS reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

A couple recent catalysts have investors excited.

As noted above, the Company just launched a new set of medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize target medicines for target ailments. These new medicinal products will be centerpieces for its new medicinal studies targeting its initial critical ailment list.

This is clearly a well-timed move, given that the legal footprint for marijuana in the US is likely to at least triple in about 5 weeks when 9 states go to the ballot boxes for related measures.

That’s good timing for the Company seeing as how it also just announced that its President, Chief Executive Officer, and Co-Founder, Mr. Raymond C. Dabney, just accepted an invitation to speak at Harvard Medical School this November.

Mr. Dabney will speak at the Dana Farber/Harvard Cancer Center, one of the largest cancer research centers in the world with more than 1,100 cancer researchers and over $600 million in cancer research funding.

He will discuss CBIS’ drug development initiatives targeting a variety of cancers, within the context of a number of other disorders, such as autism spectrum disorders, asthma, as well as pain management.

At this time, carrying a capital value in the market of $31.9M, CBIS has very little cash on the books, along with total assets exceeding $2M, which is balanced by an appreciable load ($1.67M) of total accumulated debt. In addition, the dilution in this name over the years has been so extensive that, without any reverse splits, the stock would be trading on 19.37 trillion shares at $0.000000138/share (ie, you would be rooting for a quick 7,400% rally to get back to that penny level). If you were an early investor here, you didn’t fare well. But recent catalysts have captured the mood and upcoming events may allow this one to run a bit. Over the larger time frame, we feel there are better dogs in the hunt. But CBIS is a hard fade at present. If that changes, we will be the first to let you know.  For continuing coverage on $CBIS and our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles